Wedbush Lowers MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $18.00

MoonLake Immunotherapeutics (NASDAQ:MLTX) had its price target decreased by Wedbush from $80.00 to $18.00 in a research report released on Tuesday,Benzinga reports. Wedbush currently has an outperform rating on the stock. Wedbush also issued estimates for MoonLake Immunotherapeutics’ Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.91) EPS, FY2027 earnings at ($3.60) EPS, FY2028 earnings at ($2.57) EPS and FY2029 earnings at $3.60 EPS.

Several other equities research analysts also recently weighed in on the company. BTIG Research downgraded MoonLake Immunotherapeutics from a “buy” rating to a “neutral” rating and set a $85.00 price objective on the stock. in a report on Monday. Stifel Nicolaus downgraded MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $13.00 target price on the stock. in a report on Monday. Citigroup downgraded MoonLake Immunotherapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday. Jefferies Financial Group lowered MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $8.00 price objective for the company. in a research report on Monday. Finally, Redburn Atlantic raised MoonLake Immunotherapeutics to a “hold” rating in a research report on Monday, July 28th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, MoonLake Immunotherapeutics currently has a consensus rating of “Hold” and a consensus price target of $37.00.

MoonLake Immunotherapeutics Trading Up 5.7%

NASDAQ MLTX opened at $7.46 on Tuesday. The company has a quick ratio of 16.65, a current ratio of 16.65 and a debt-to-equity ratio of 0.21. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75. The company has a market cap of $479.16 million, a price-to-earnings ratio of -2.68 and a beta of 1.11. The business’s fifty day moving average is $50.88 and its 200 day moving average is $45.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.14). During the same quarter in the prior year, the business earned ($0.39) earnings per share. As a group, sell-side analysts expect that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Bihua Chen sold 5,827 shares of the business’s stock in a transaction dated Tuesday, September 30th. The stock was sold at an average price of $6.96, for a total value of $40,555.92. Following the completion of the sale, the insider directly owned 1,994,173 shares of the company’s stock, valued at $13,879,444.08. The trade was a 0.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 12.02% of the stock is owned by insiders.

Institutional Trading of MoonLake Immunotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MLTX. Nuveen LLC bought a new stake in MoonLake Immunotherapeutics in the 1st quarter valued at about $26,308,000. Vestal Point Capital LP boosted its stake in MoonLake Immunotherapeutics by 175.0% during the 2nd quarter. Vestal Point Capital LP now owns 550,000 shares of the company’s stock valued at $25,960,000 after purchasing an additional 350,000 shares during the last quarter. Balyasny Asset Management L.P. boosted its stake in MoonLake Immunotherapeutics by 436.8% during the 2nd quarter. Balyasny Asset Management L.P. now owns 423,170 shares of the company’s stock valued at $19,974,000 after purchasing an additional 344,335 shares during the last quarter. Millennium Management LLC boosted its stake in MoonLake Immunotherapeutics by 3,343.2% during the 1st quarter. Millennium Management LLC now owns 344,320 shares of the company’s stock valued at $13,453,000 after purchasing an additional 334,320 shares during the last quarter. Finally, Octagon Capital Advisors LP acquired a new position in MoonLake Immunotherapeutics during the 1st quarter valued at about $11,565,000. 93.85% of the stock is owned by institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.